Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as ...

Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the ...

Callander, MD, discussed the rationale for a quadruplet regimen being evaluated in patients with relapsed/refractory multiple ...

Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with ...

A clinical trial of adjuvant intismeran (V940) with or without pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) in high-risk stage I non-small cell lung cancer (V940-014) ...

Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.

A growing number of anticancer therapies once available only as intravenous (IV) infusions now have subcutaneous formulations. These can shorten chair time for patients and change how infusion centers ...

Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer. In an interview with ...

Emory University Hospital was recently selected as the first medical center to adopt the Liberty endovascular robotic system, developed by Microbot Medical and granted 510(k) clea ...

A clinical trial of adjuvant intismeran (V940) with or without pembrolizumab coformulated with berahyaluronidase alfa ...

Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.

Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC. The TRIPL trial (NCT06865339) is testing thoracic ...